Artivion Inc AORT

$18.16 -0.37 (-2.00%)

Valuation

Market cap
886,026,000
Revenue TTM
$441,330,000
Net income TTM
$9,770,000
P/E (trailing)
40.28
P/E (forward)
3,706.00
Profit margin
2.21%
Debt to equity
0.81

Trading

Volume
642,100
Avg volume
691,004
Day's range
$18.13 – $18.93
Shares out
48,790,000
Stochastic %K
2%
Beta
1.31
Analysts
Strong Buy
Price target
$38.47

Price

Company profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXU...

Show more

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Industry
Medical Devices
Sector
Healthcare
Phone
770 419 3355
Website
https://artivion.com
Address
1655 Roberts Boulevard NW, Kennesaw, United States

Latest news

Stocktwits

GTA_Terminal Nov 9, 2:34 AM
Dark pool check on $AORT: what traded off the exchanges in the latest session. That came on a day the stock dropped hard, so the question is whether big holders were buying the dip or heading for the exit. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=AORT&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=AORT Read the full article for the full details: https://globaltradersacademy.com/articles/aort-technical-levels-chart-options-flow-and-dark-pools-diverge-at-20-21?utm_source=stocktwits&utm_medium=social
0 replies
GTA_Terminal Nov 7, 2:07 AM
Dark pool check on $AORT: what traded off the exchanges this session. That came on a day the stock dropped hard, so the question is whether big holders were buying the dip or heading for the exit. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=AORT&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=AORT Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-activity-unusual-off-exchange-trading-in-artivion-aort?utm_source=stocktwits&utm_medium=social
0 replies
flychicken1991 Nov 5, 10:20 PM
$AORT Artivion Reports Third Quarter 2026 Financial Results. Impact: Mixed (82%). Falling adjusted earnings and weaker profit margins pressure AORT's earnings-based valuation, while growing product revenue and maintained annual guidance midpoints provide offsetting support. Source and what to watch next: https://nimpact.tech/newsimpact/news/362a048d85559815/aort-artivion-reports-third-quarter-2026-financial-results?utm_source=stocktwits&utm_medium=story_url
0 replies
StocktwitsEarnings Nov 5, 9:14 PM
$AORT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.08 down -50.00% YoY • Reported revenue of $123.79M up 9.17% YoY • Artivion narrowed full-year 2026 revenue expectations to $484M, representing adjusted constant currency growth of 8% to 10%, and adjusted EBITDA expectations to $93M.
0 replies
Georgia80 Oct 12, 2:21 AM
$AORT Management reaffirmed full-year guidances..
0 replies
Georgia80 Oct 12, 2:18 AM
$AORT Has Expanded aortic arch product portfolio[.
0 replies
Georgia80 Oct 12, 2:16 AM
$AORT 2 important product lines are growing.
0 replies
Georgia80 Oct 12, 2:15 AM
$AORT FDA approval creates a growth catalyst//
0 replies